Advanced in Riboflavin Transporter Deficiency Neuronopathy

Ian R. Woodcock

Melbourne, VIC, AU 
Advanced in Riboflavin Transporter Deficiency Neuronopathy
Melbourne, VIC, AU 
OverviewLocationsClinical Research

Overview

Ian Woodcock practices in Melbourne, Australia. Mr. Woodcock is rated as an Advanced expert by MediFind in the treatment of Riboflavin Transporter Deficiency Neuronopathy. His top areas of expertise are Riboflavin Transporter Deficiency Neuronopathy, Primary Lateral Sclerosis, Facioscapulohumeral Muscular Dystrophy (FSHD), and Becker Muscular Dystrophy.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Riboflavin Transporter Deficiency Neuronopathy.

Gender
Male

Locations

Melbourne, VIC, Australia
Other Locations
Parkville, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Effect of Creatine Monohydrate on Functional Muscle Strength and Muscle Mass in Children With FSHD: a Multi-centre, Randomised, Double-blind Placebo-controlled Crossover Trial
Effect of Creatine Monohydrate on Functional Muscle Strength and Muscle Mass in Children With FSHD: a Multi-centre, Randomised, Double-blind Placebo-controlled Crossover Trial
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Dietary supplement
Study Phase: Not Applicable
View 2 Less Clinical Trials

23 Total Publications

Detailed immune cell profiling of paediatric patient with limb girdle muscular dystrophy R3.
Detailed immune cell profiling of paediatric patient with limb girdle muscular dystrophy R3.
Journal: Journal of the neurological sciences
Published: March 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Woodcock's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile